Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.
Seema Mehta SteinkeMona AlfaresAlexandra ValsamakisShmuel ShohamRavit Arav-BogerLaura LeesDarin OstranderMichael S FormanAudra ShedeckRichard F AmbinderRichard John JonesRobin K AveryPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
In the absence of good therapeutic alternatives, CDV is used in GCV-R/refractory CMV infection. However, it is associated with a substantial risk of toxicity and failure to clear CMV DNAemia, highlighting the need for development of newer and less toxic therapies. The high mortality in this group of patients underscores the severity of illness in this population.